YKL-40, cardiovascular events, and mortality in individuals recently diagnosed with type 2 diabetes: A Danish cohort study
YKL-40 is a prognostic biomarker for most CVEs, and even more so for all-cause mortality, primarily driven by cancer-related causes.
Authors
- Kurt Højlund (ORCID: https://orcid.org/0000-0002-0891-4224)
- Alisa D. Kjærgaard (ORCID: https://orcid.org/0000-0003-3899-1324)
- Verena Hirschberg (ORCID: https://orcid.org/0000-0002-3600-1430)
- Reimar W. Thomsen (ORCID: https://orcid.org/0000-0001-9135-3474)
- Michael Hecht Olsen (ORCID: https://orcid.org/0000-0003-2230-5780)
- Niels Jessen (ORCID: https://orcid.org/0000-0001-5613-7274)
- Peter Vestergaard (ORCID: https://orcid.org/0000-0002-9046-2967)
- Allan Vaag (ORCID: https://orcid.org/0000-0002-3690-2191)
- Torben Hansen (ORCID: https://orcid.org/0000-0001-8748-3831)
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Aalborg University Hospital (DK)
- Novo Nordisk Foundation (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Holbæk Sygehus (DK)
Publication Details
- Journal
- Diabetes Research and Clinical Practice
- Published
- 2024-12-22
- DOI
- https://doi.org/10.1016/j.diabres.2024.111970
- Citations
- 2
- Primary Topic
- Studies on Chitinases and Chitosanases
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Novo Nordisk
- Vetenskapsrådet
- Novo Nordisk Fonden
- Diabetesforeningen